Pfizer releases Paloma-2 sub-analysis study data

The data was presented at the second ESMO Asia Congress. | Courtesy of Shutterstock

Pfizer has released the results of a sub-analysis that is
part of the phase 3 Paloma-2 clinical trial involving Ibrance combined with
letrozole.

The sub-analysis studied Asian patients participating in the trial
and showed that the combination significantly extended progression-free survival (PFS).

The Ibrance-letrozole combination was evaluated for the
first-line treatment of women who are postmenopausal and estrogen
receptor-positive.

“It is exciting to see that the significant efficacy shown
in the Paloma-2 trial extends to Asian patients, further supporting the
potential for Ibrance to be a standard of care treatment in Asia Pacific, a
region where more than 600,000 women are affected by breast cancer each year,”
Pfizer Oncology Regional Medical Lead Dr. Mahmood
Alam said.

Data from the sub-analysis from the phase 3 Paloma-2
trial was presented at the second ESMO Asia Congress in Singapore.

“Across the Asia Pacific region, breast cancer has grown
into a major health concern, with significant increases in breast cancer
incidence in recent years in several Asian countries,” Dr. Seock-Ah Im,
who works at the Seoul National University Hospital, said. “Patients with metastatic
breast cancer, in particular those in Asia, eagerly await new and innovative
treatment options.”